Results 11 to 20 of about 320,703 (320)

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study

Haematologica, 2018
We have previously described the safety and efficacy of pegylated interferon-α2a therapy in a cohort of 62 patients with myeloproliferative neoplasm-associated myelofibrosis followed in centers affiliated to the French Intergroup of Myeloproliferative ...
Jean-Christophe Ianotto, Aurélie Chauveau, Françoise Boyer-Perrard, Emmanuel Gyan, Kamel Laribi, Pascale Cony-Makhoul, Jean-Loup Demory, Benoit de Renzis, Christine Dosquet, Jerome Rey, Lydia Roy, Brigitte Dupriez, Laurent Knoops, Laurence Legros, Mohamed Malou, Pascal Hutin, Dana Ranta, Omar Benbrahim, Valérie Ugo, Eric Lippert, Jean-Jacques Kiladjian   +20 more
doaj   +2 more sources

Pegylated interferon for treating severe recurrent respiratory papillomatosis in a child: case report

São Paulo Medical Journal, 2017
CONTEXT: Recurrent respiratory papillomatosis (RRP) is the most common laryngeal tumor. During childhood, it may present in extremely severe forms defined by the need for frequent surgical procedures to relieve respiratory distress and/or involvement of ...
Rebecca Maunsell, Maria Angela Bellomo-Brandão   +1 more
doaj   +2 more sources

Early Treatment with Pegylated Interferon Lambda for Covid-19. [PDF]

N Engl J Med, 2023
Background The efficacy of a single dose of pegylated interferon lambda in preventing clinical events among outpatients with acute symptomatic coronavirus disease 2019 (Covid-19) is unclear.
Reis G, Moreira Silva EAS, Medeiros Silva DC, Thabane L, Campos VHS, Ferreira TS, Santos CVQ, Nogueira AMR, Almeida APFG, Savassi LCM, Figueiredo-Neto AD, Dias ACF, Freire Júnior AM, Bitarães C, Milagres AC, Callegari ED, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Wilson LA, Forrest JI, Ruton H, Sprague S, McKay P, Guo CM, Limbrick-Oldfield EH, Kanters S, Guyatt GH, Rayner CR, Kandel C, Biondi MJ, Kozak R, Hansen B, Zahoor MA, Arora P, Hislop C, Choong I, Feld JJ, Mills EJ, Glenn JS, TOGETHER Investigators.   +41 more
europepmc   +2 more sources

Pegylated Interferon Alfa [PDF]

Definitions, 2020
openaire   +2 more sources

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis

Viruses, 2022
Ropeginterferon alfa-2b is a novel mono-pegylated and extra-long-acting interferon, being developed for the treatment of myeloproliferative neoplasm (MPN) and chronic viral hepatitis.
Yi-Wen Huang, A. Qin, Chan-Yen Tsai, Pei‐Jer Chen   +3 more
semanticscholar   +1 more source

NAFLD‐related hepatocellular carcinoma: The growing challenge

Hepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison   +2 more
wiley   +1 more source

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B

Hepatology International, 2020
Ropeginterferon alfa-2b is a novel mono-pegylated interferon that has only one major form as opposed to 8–14 isomers of other on-market pegylated interferon, allowing injection every two or more weeks with higher tolerability.
Yi-Wen Huang, Chao-Wei Hsu, Sheng-Nan Lu, Ming‐Lung Yu, C. Su, W. Su, R. Chien, Ching-Sheng Hsu, Shih-Jer Hsu, H. Lai, A. Qin, K. Tseng, Pei‐Jer Chen   +12 more
semanticscholar   +1 more source

Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity

Nature Communications, 2022
The interferon response is a critical component response to SARS-CoV-2 infection and prior studies have established a role for the administration of PEGylated interferon-lambda1 and its impact on viral clearance.
Deanna M. Santer, Daniel Li, Yanal Ghosheh, Muhammad Atif Zahoor, Dhanvi Prajapati, Bettina E. Hansen, D. Lorne J. Tyrrell, Jordan J. Feld, Adam J. Gehring   +8 more
doaj   +1 more source

Raised serum transaminases during treatment with pegylated interferon for chronic hepatiti C [PDF]

, 2016
Introduction : Serum transaminases rose significantly in 7 patients with chronic hepatitis C, genotypes 2 and 3, who were treated with pegylated interferon and ribavirin. Methods : 219 patients with chronic hepatitis C, genotypes 2 and 3, were treated
Datta, S., Mandalou, P., Mills, P.R., Spence, E.   +3 more
core   +1 more source

Thyrotoxicosis With Pegylated Interferon Alfa-2b [PDF]

Archives of Dermatology, 2010
Despite adequate surgery, a diagnosis of stage III melanoma carries a high risk of relapse, and hence mortality. Interferon alfa is the only treatment that has currently been shown to alter the natural history of the disease, delaying relapse-free survival, particularly in patients with micrometastatic disease.
Lowndes, SA, Asher, R, Middleton, MR
openaire   +2 more sources